Titolo/oggetto del contratto di sperimentazione
An open label study followed by a randomised, double-blind, placebocontrolled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC)